IDO1 and melanoma: Studies using the murine B16.SIY melanoma mouse model have shown that combinations of CTLA-4 or PD-1/PD-L1 with IDO blockade restored both IL-2 production and CD8+ T cell proliferation within the TME (48), pointing to the potential merits of a combinational targeting approach.